IH Interests: Neurovascular

Route 92 Medical’s Monopoint® Operating Platform Shows 82% First Pass Effect in Independent Study
Route 92 Medical Receives the First FDA Clearance for a Complete Stroke Treatment System
Route 92 Medical Announces Impressive Clinical Results for its Tenzing® Technology.
Route 92 Medical Raises Over $31 Million in Oversubscribed Series F Equity Financing to Accelerate its Commercialization into the Rapidly Growing Stroke Treatment Market
Route 92 Medical Announces $50 Million Series F Extension Equity Financing
Route 92 Medical Gains EU and MDSAP Certification for its Neurovascular Stroke-Intervention-Focused Product Portfolio
,
Route 92 Medical Announces Results of SUMMIT MAX Clinical Trial Showing Highest First Pass Effect Ever Reported in a Randomized Endovascular Stroke Thrombectomy Study